Reported 9,602 shares, up 7,369 (330.0%) from the prior quarter.
Reported value 266.8%; share count 330.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2015-06-30 | 6869000 |
| 2015-09-30 | 35997000 |
| 2015-12-31 | 44828000 |
| 2016-03-31 | 36242000 |
| 2016-06-30 | 19938000 |
| 2016-09-30 | 7884000 |
| 2016-12-31 | 0 |
| 2017-03-31 | 566000 |
| 2017-06-30 | 1489000 |
| 2017-09-30 | 313000 |
| 2017-12-31 | 1148000 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q4 2017 | Added | 9,602 | +7,369 (330.0%) | 0.05% | $1,148,000 | 2018-02-14 | |
| Q3 2017 | Reduced | 2,233 | -10,001 (-81.7%) | 0.02% | $313,000 | 2017-11-14 | |
| Q2 2017 | Added | 12,234 | +7,567 (162.1%) | 0.08% | $1,489,000 | 2017-08-14 | |
| Q1 2017 | New | 4,667 | +4,667 (0.0%) | 0.03% | $566,000 | 2017-05-15 | |
| Q4 2016 | Reduced | 0 | -64,341 (-100.0%) | 0 | $0 | 2017-02-14 | |
| Q3 2016 | Reduced | 64,341 | -106,420 (-62.3%) | 0.24% | $7,884,000 | 2016-11-14 | |
| Q2 2016 | Reduced | 170,761 | -89,562 (-34.4%) | 0.6% | $19,938,000 | 2016-08-16 | |
| Q1 2016 | Added | 260,323 | +25,313 (10.8%) | 1.03% | $36,242,000 | 2016-05-16 | |
| Q4 2015 | Added | 235,010 | +4,834 (2.1%) | 1.43% | $44,828,000 | 2016-02-16 | |
| Q3 2015 | Added | 230,176 | +192,176 (505.7%) | 0.95% | $35,997,000 | 2015-11-16 | |
| Q2 2015 | New | 38,000 | +38,000 (0.0%) | 0.18% | $6,869,000 | 2015-08-14 |
Who else reported the position
574 managers reported * ALEXION PHARMACEUTICALS INC for Q4 2017.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| PRICE T ROWE ASSOCIATES INC MD | Reduced | 21,006,788 | -1,274,860 | 0.41% | $2,512,202,000 | 19 qtrs |
| BlackRock Inc | Reduced | 18,004,610 | -1,352,721 | 0.1% | $2,153,171,000 | 19 qtrs |
| FMR LLC | Reduced | 17,674,124 | -1,284,809 | 0.25% | $2,113,648,000 | 19 qtrs |
| VANGUARD GROUP INC | Added | 15,202,754 | +161,204 | 0.08% | $1,818,097,000 | 19 qtrs |
| STATE STREET CORPORATION | Reduced | 10,841,065 | -413,494 | 0.1% | $1,296,489,000 | 9 qtrs |
| BAKER BROS ADVISORS LP | Unchanged | 8,553,864 | 0 | 8.87% | $1,022,957,000 | 11 qtrs |
| AMERIPRISE FINANCIAL INC | Added | 7,116,247 | +725,946 | 0.39% | $849,804,000 | 19 qtrs |
| JENNISON ASSOCIATES LLC | Reduced | 5,021,165 | -311,471 | 0.59% | $600,481,000 | 19 qtrs |
| SANDS CAPITAL MANAGEMENT LLC | Reduced | 4,553,095 | -222,852 | 1.65% | $544,505,000 | 19 qtrs |
| The Goldman Sachs Group Inc | Added | 4,144,436 | +686,209 | 0.12% | $495,632,000 | 19 qtrs |
Filing details and methodology As reported
- Report period
- December 31, 2017
- Filed
- February 14, 2018
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
- Sole
- 9,602
- Shared
- 0
- None
- 0
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.